Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal for ImmunoTherapy of Cancer

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Confidence Interval

Show all topics

DOI

10.1186/s40425-019-0623-z

License

CC-BY

Other Formats

PDF